We have seen a steady increase in the use of blood based biomarkers, the conversion rates from ... announcement this morning, favoring Wegovy over Zepbound, there are clearly some investor ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Zepbound, in favor of Novo Nordisk’s (NVO) rival drug, Wegovy. In a press release, the Danish drugmaker said that from July 1, CVS Caremark, the largest pharmacy benefit manager in the U.S., has ...

LONDON-The World Health Organisation (WHO) plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on May 1 shows, marking a ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical company.

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be ...